Greg Wilding

1.5k total citations
30 papers, 671 citations indexed

About

Greg Wilding is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Experimental and Cognitive Psychology. According to data from OpenAlex, Greg Wilding has authored 30 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Experimental and Cognitive Psychology. Recurrent topics in Greg Wilding's work include Phonetics and Phonology Research (7 papers), Voice and Speech Disorders (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Greg Wilding is often cited by papers focused on Phonetics and Phonology Research (7 papers), Voice and Speech Disorders (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Greg Wilding collaborates with scholars based in United States, Australia and Italy. Greg Wilding's co-authors include Kris Tjaden, Jennifer Lam, Joan E. Sussman, Raymond P. Briñas, Andreas Sundgren, Wei Deng, Susan Morey, Joseph J. Barchi, Kate Rittenhouse‐Olson and Grace Liu and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and The American Journal of Gastroenterology.

In The Last Decade

Greg Wilding

29 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Greg Wilding United States 12 269 235 139 106 100 30 671
Sarah Schneider United States 14 326 1.2× 88 0.4× 61 0.4× 211 2.0× 82 0.8× 56 704
Yuki Koike Japan 13 127 0.5× 56 0.2× 73 0.5× 57 0.5× 27 0.3× 41 448
Michael Klotz Germany 8 255 0.9× 83 0.4× 41 0.3× 208 2.0× 101 1.0× 29 423
Courtney Lewis United States 11 117 0.4× 26 0.1× 76 0.5× 62 0.6× 17 0.2× 24 657
Ben W.R. Balzer Australia 11 55 0.2× 40 0.2× 249 1.8× 13 0.1× 44 0.4× 19 874
Franz Stanzel Germany 21 115 0.4× 72 0.3× 56 0.4× 42 0.4× 7 0.1× 85 1.6k
Anne Faber Germany 16 91 0.3× 29 0.1× 166 1.2× 9 0.1× 13 0.1× 44 874
E Ruud Norway 12 149 0.6× 95 0.4× 112 0.8× 8 0.1× 13 0.1× 29 539
Michiaki Hiramoto Japan 9 493 1.8× 108 0.5× 47 0.3× 377 3.6× 20 0.2× 17 722
Douglas Wood United States 13 13 0.0× 7 0.0× 118 0.8× 43 0.4× 25 0.3× 29 644

Countries citing papers authored by Greg Wilding

Since Specialization
Citations

This map shows the geographic impact of Greg Wilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Wilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Wilding more than expected).

Fields of papers citing papers by Greg Wilding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Wilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Wilding. The network helps show where Greg Wilding may publish in the future.

Co-authorship network of co-authors of Greg Wilding

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Wilding. A scholar is included among the top collaborators of Greg Wilding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Wilding. Greg Wilding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tjaden, Kris, et al.. (2013). Acoustic and Perceptual Consequences of Clear and Loud Speech. Folia Phoniatrica et Logopaedica. 65(4). 214–220. 35 indexed citations
3.
Tjaden, Kris, Jennifer Lam, & Greg Wilding. (2013). Vowel Acoustics in Parkinson's Disease and Multiple Sclerosis: Comparison of Clear, Loud, and Slow Speaking Conditions. Journal of Speech Language and Hearing Research. 56(5). 1485–1502. 112 indexed citations
4.
Lam, Jennifer, Kris Tjaden, & Greg Wilding. (2012). Acoustics of Clear Speech: Effect of Instruction. Journal of Speech Language and Hearing Research. 55(6). 1807–1821. 91 indexed citations
5.
O’Malley, Rebecca L., Matthew H. Hayn, Greg Wilding, & Thomas Schwaab. (2012). Population-based analysis of cancer control of partial nephrectomy for high-risk localized renal cell carcinoma.. Journal of Clinical Oncology. 30(5_suppl). 385–385. 1 indexed citations
6.
Tjaden, Kris & Greg Wilding. (2011). Speech and pause characteristics associated with voluntary rate reduction in Parkinson's disease and Multiple Sclerosis. Journal of Communication Disorders. 44(6). 655–665. 34 indexed citations
7.
Chanan‐Khan, Asher, Kasyapa S. Chitta, Aneel Paulus, et al.. (2011). Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British Journal of Haematology. 155(4). 457–467. 58 indexed citations
8.
9.
Tjaden, Kris & Greg Wilding. (2010). The Impact of Rate Reduction and Increased Loudness on Fundamental Frequency Characteristics in Dysarthria. Folia Phoniatrica et Logopaedica. 63(4). 178–186. 30 indexed citations
10.
Tjaden, Kris & Greg Wilding. (2010). Effects of speaking task on intelligibility in Parkinson's disease. Clinical Linguistics & Phonetics. 25(2). 155–168. 44 indexed citations
11.
12.
Jeraj, Robert, et al.. (2008). Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. Journal of Clinical Oncology. 26(15_suppl). 3515–3515. 9 indexed citations
13.
Houk, Brett E., Carlo L. Bello, M. Dror Michaelson, et al.. (2007). 4505 ORAL A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). European Journal of Cancer Supplements. 5(4). 300–300. 6 indexed citations
14.
Kondagunta, G. Varuni, G. R. Hudes, Robert A. Figlin, et al.. (2007). 4520 POSTER Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study. European Journal of Cancer Supplements. 5(4). 305–305. 1 indexed citations
15.
Rini, Brian I., Greg Wilding, G. R. Hudes, et al.. (2007). 4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. European Journal of Cancer Supplements. 5(4). 300–300. 7 indexed citations
16.
Arora, Pradeep, et al.. (2006). Care of elderly patients with chronic kidney disease. International Urology and Nephrology. 38(2). 363–370. 9 indexed citations
17.
Chang, Julie, Anne M. Traynor, Jill Kolesar, et al.. (2006). A phase I study of triapine in combination with doxorubicin in refractory tumors. Journal of Clinical Oncology. 24(18_suppl). 13168–13168. 1 indexed citations
18.
Holen, Kyle D., Samira Syed, Alison L. Hannah, et al.. (2004). Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2024–2024. 23 indexed citations
19.
Koch, Kevin M., Andrew G. Stead, M. Versola, et al.. (2003). 559 Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. European Journal of Cancer Supplements. 1(5). S169–S169. 11 indexed citations
20.
Schulz, Craig, H. I. Robins, Behnam Badie, et al.. (1997). 9 Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical and thymidine replacement study. International Journal of Radiation Oncology*Biology*Physics. 39(2). 139–139. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Schneider Breakdown of academic impact, for papers by Yuki Koike Breakdown of academic impact, for papers by Michael Klotz Breakdown of academic impact, for papers by Courtney Lewis Breakdown of academic impact, for papers by Ben W.R. Balzer Breakdown of academic impact, for papers by Franz Stanzel Breakdown of academic impact, for papers by Anne Faber Breakdown of academic impact, for papers by E Ruud Breakdown of academic impact, for papers by Michiaki Hiramoto Breakdown of academic impact, for papers by Douglas Wood
Rankless by CCL
2026